Nctid:
NCT00000322
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-09-05"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000019969", "term"=>"Amphetamine-Related Disorders"}], "ancestors"=>[{"id"=>"D000019966", "term"=>"Substance-Related Disorders"}, {"id"=>"D000064419", "term"=>"Chemically-Induced Disorders"}, {"id"=>"D000001523", "term"=>"Mental Disorders"}], "browseLeaves"=>[{"id"=>"M21840", "name"=>"Amphetamine-Related Disorders", "asFound"=>"Amphetamine-Related Disorders", "relevance"=>"HIGH"}, {"id"=>"M21837", "name"=>"Substance-Related Disorders", "relevance"=>"LOW"}, {"id"=>"M30302", "name"=>"Chemically-Induced Disorders", "relevance"=>"LOW"}, {"id"=>"M4815", "name"=>"Mental Disorders", "relevance"=>"LOW"}, {"id"=>"M14473", "name"=>"Psychotic Disorders", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Substance Related Disorders", "abbrev"=>"BC25"}, {"name"=>"Behaviors and Mental Disorders", "abbrev"=>"BXM"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M11674", "name"=>"Methamphetamine", "relevance"=>"LOW"}, {"id"=>"M3997", "name"=>"Amphetamine", "relevance"=>"LOW"}, {"id"=>"T22", "name"=>"Tyrosine", "asFound"=>"Fibromyalgia", "relevance"=>"HIGH"}], "browseBranches"=>[{"name"=>"Central Nervous System Stimulants", "abbrev"=>"CNSSti"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}, {"name"=>"Amino Acids", "abbrev"=>"AA"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["PHASE2"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"RANDOMIZED", "maskingInfo"=>{"masking"=>"DOUBLE"}, "primaryPurpose"=>"TREATMENT"}, "enrollmentInfo"=>{"count"=>89}}, "statusModule"=>{"overallStatus"=>"COMPLETED", "startDateStruct"=>{"date"=>"1997-04"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"1997-04", "completionDateStruct"=>{"date"=>"2001-12"}, "lastUpdateSubmitDate"=>"2017-01-11", "studyFirstSubmitDate"=>"1999-09-20", "studyFirstSubmitQcDate"=>"1999-09-20", "lastUpdatePostDateStruct"=>{"date"=>"2017-01-12", "type"=>"ESTIMATED"}, "studyFirstPostDateStruct"=>{"date"=>"1999-09-21", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Craving"}, {"measure"=>"Drug use"}, {"measure"=>"Retention"}, {"measure"=>"Functioning"}]}, "conditionsModule"=>{"keywords"=>["amphetamine dependence"], "conditions"=>["Amphetamine-Related Disorders"]}, "descriptionModule"=>{"briefSummary"=>"The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving.\"", "detailedDescription"=>"Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment and craving."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "maximumAge"=>"65 years", "minimumAge"=>"18 years", "healthyVolunteers"=>false, "eligibilityCriteria"=>"Inclusion Criteria:\n\n18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.\n\nExclusion Criteria:\n\nNo dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance."}, "identificationModule"=>{"nctId"=>"NCT00000322", "briefTitle"=>"Tyrosine for Methamphetamine Dependence - 1", "organization"=>{"class"=>"NIH", "fullName"=>"National Institute on Drug Abuse (NIDA)"}, "officialTitle"=>"Tyrosine for Methamphetamine Dependence", "orgStudyIdInfo"=>{"id"=>"NIDA-10739-1"}, "secondaryIdInfos"=>[{"id"=>"R01-10739-1"}]}, "armsInterventionsModule"=>{"interventions"=>[{"name"=>"Tyrosine", "type"=>"BEHAVIORAL"}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"94117", "city"=>"San Francisco", "state"=>"California", "country"=>"United States", "facility"=>"Haight Ashbury Free Clinics", "geoPoint"=>{"lat"=>37.77493, "lon"=>-122.41942}}], "overallOfficials"=>[{"name"=>"Gantt Galloway, Pharm.D.", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"Haight Ashbury Free Clinics"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"National Institute on Drug Abuse (NIDA)", "class"=>"NIH"}}}}